Plain-English translation of NCT07604896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing lecanemab, an antibody medication designed to target amyloid protein buildup in the brain—a hallmark of Alzheimer's disease. Researchers want to understand whether this medication can slow cognitive decline and is safe to use in people with early Alzheimer's or mild memory problems. The study will track participants over 24 months using brain imaging, eye scans, and thinking tests to see how well the treatment works and monitor for side effects.
Alzheimer's disease causes progressive memory loss and thinking problems, and there are limited treatment options available today. This medication represents a newer approach that aims to clear amyloid from the brain before severe damage occurs, potentially helping people in the earliest stages of the disease.
You likely qualify if…
You likely don't qualify if…
You would receive the medication (or standard care, depending on random assignment) and visit the research clinic at baseline, and then at 6, 12, 18, and 24 months. At each visit, you'll undergo brain MRI scans, eye imaging, cognitive testing (memory and thinking assessments), and blood work to monitor safety. Your caregiver will be involved throughout to help track how you're doing and ensure you're taking the treatment correctly.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China